grant
Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy
Organization CHILDREN'S HOSPITAL OF LOS ANGELESLocation LOS ANGELES, UNITED STATESPosted 1 Apr 2023Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY20260-11 years oldAbateAcquired brain injuryAcute B-Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Lymphoid LeukemiaAdoptionAdverse effectsAntigen TargetingAttentionB Cell Antigen CD19B cell progenitor acute lymphoblastic leukemiaB-ALLB-Cell Acute Lymphocytic LeukemiaB-Cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-Lymphocyte Antigen CD19B-Lymphocyte Surface Antigen B4B-cell ALLB-cell precursor acute lymphoblastic leukemiaBehaviorBehavior Conditioning TherapyBehavior ModificationBehavior TherapyBehavior TreatmentBehavioralBehavioral Conditioning TherapyBehavioral ModificationBehavioral SymptomsBehavioral TherapyBehavioral TreatmentBiological MarkersBlood - brain barrier anatomyBlood SampleBlood SerumBlood flowBlood specimenBlood-Brain BarrierBrainBrain InjuriesBrain Nervous SystemBrain imagingCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD19CD19 AntigensCD19 geneCD19 moleculeCerebral EdemaCharacteristicsChildChild YouthChildren (0-21)ClinicalClinical TrialsClinical assessmentsCognitionCognitiveCognitive DisturbanceCognitive ImpairmentCognitive ManifestationsCognitive SymptomsCognitive declineCognitive function abnormalConditioning TherapyCytometryDataDeliriumDevelopmentDifferentiation Antigen CD19DiffuseDisturbance in cognitionDoseDysfunctionDysphasiaEarly identificationEncephalonEncephalopathiesEndothelial CellsFunctional disorderFutureGuidelinesHemato-Encephalic BarrierICANSIQ DeficitImmediate MemoryImmuneImmune MarkersImmune MonitoringImmune responseImmune systemImmunesImmunologic MarkersImmunologic MonitoringImmunologic SubtypingImmunological MonitoringImmunomonitoringImmunophenotypingImpaired cognitionImpairmentIn complete remissionInflammationInflammation MediatorsInflammatoryInflammatory ResponseInfusionInfusion proceduresIntermediary MetabolismInterventionLeannessLeu 12Leukemic CellLifeLong-Term EffectsLong-term cohort studyLongitudinal cohort studyMR ImagingMR TomographyMRIMRI biomarkerMRI markerMRIsMachine LearningMagnetic Resonance ImagingMeasuresMediatingMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMetabolicMetabolic ProcessesMetabolismMonitorNMR ImagingNMR TomographyNerve CellsNerve UnitNervous System PoisoningNeural CellNeurocognitive DeficitNeurocyteNeurologicNeurologic ManifestationsNeurologic Signs and SymptomsNeurologic SymptomsNeurologicalNeurological ManifestationsNeurological Signs and SymptomsNeuronal InjuryNeuronsNeuropsychologic TestsNeuropsychological TestsNeurotoxic DisordersNeurotoxicity SyndromesNeurotoxin DiseasesNeurotoxin DisordersNuclear Magnetic Resonance ImagingOutcomePathway interactionsPatientsPhysiopathologyPilot ProjectsPre-B-Cell LeukemiaPrecursor B Lymphoblastic LeukemiaPrecursor Cell Lymphoblastic LeukemiaPrecursor Lymphoblastic LeukemiaPreventative interventionPreventative treatmentPreventive treatmentPrior ChemotherapyPrior Chemotherapy RegimensProductionPublishingRecommendationRefractoryRelapseResolutionRiskSerumSeveritiesShort-Term MemoryStructureSurrogate MarkersSymptomsT cells for CART-Cell ActivationThinnessTimeZeugmatographyactivate T cellsacute lymphatic leukemiaacute lymphogenous leukemiaacute lymphomatic leukemiaadverse consequenceadverse outcomebehavior interventionbehavior outcomebehavioral interventionbehavioral outcomebio-markersbiologic markerbiomarkerbloodbrain barrierbrain MR imagingbrain MRIbrain abnormalitiesbrain basedbrain damagebrain magnetic resonance imagingbrain visualizationbrain-injuredcerebral MR imagingcerebral MRIcerebral magnetic resonance imagingchimeric antigen T cell receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellscognitive changecognitive dysfunctioncognitive losscognitive trainingcomplete responsecytokinedeliriousdensitydevelopmentaleffective therapyeffective treatmenthigh riskhost responseimaging biomarkerimaging markerimaging-based biological markerimaging-based biomarkerimaging-based markerimmune cell therapy associated neurologic toxicityimmune effector cell mediated neurotoxicity syndromeimmune effector cell-associated neurotoxicityimmune effector cell-associated neurotoxicity syndromeimmune system responseimmune-based biomarkersimmunological biomarkersimmunological markersimmunoresponseinflammation markerinflammatory markerinflammatory mediatorinfusionsintelligence quotient deficitintervention for preventionkidsleukemialong-term sequelaemachine based learningmachine learned algorithmmachine learning algorithmmachine learning based algorithmmagnetic resonance imaging biomarkermagnetic resonance imaging markermulti-modalitymultimodalityneural imagingneural manifestationneuro-imagingneurocognitive declineneurocognitive impairmentneurocognitive testneuroimagingneuroimaging biomarkerneuroimaging markerneurological imagingneuron injuryneuron toxicityneuronalneuronal toxicityneuroprotectionneuroprotectiveneurotoxicitynew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathophysiologypathwayperipheral bloodpilot studyprediction algorithmpredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreventpreventingprevention interventionpreventional intervention strategypreventive interventionprocessing speedprospectiveresolutionsside effectsmall molecular inhibitorsmall molecule inhibitorsubstantia albasurrogate bio-markerssurrogate biomarkerswhite matterworking memoryyoungster
Description preview
Project Summary
CD19-directed chimeric antigen receptor (CAR)-T cell therapy for relapsed or refractory B-cell acute
lymphoblastic leukemia (ALL) induces complete remission in 70-90% of otherwise incurable patients. CAR-T
cell engagement with their target antigens induces expansion of activated CAR-T cells, producing cytokines
and other…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click